Lannett Company, Inc. announced successful results from a placebo-controlled phase III clinical study evaluating C-Topical (cocaine hydrochloride solution) 4% and 10% as a local anesthetic for diagnostic procedures or surgeries on or through the inside of the nose.
The 646-patient study met all primary clinical endpoints of the trial and had a statistically significant treatment effect for both the 4% and the 10% solutions. Toxicology and pharmacokinetic studies are ongoing and expected to be completed by year end.
"We are very pleased by the positive phase III results for C-Topical," said Arthur Bedrosian, chief executive officer of Lannett. "Upon the successful completion of the toxicology and pharmacokinetic studies for C-Topical, our plan is to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) during the summer of 2017. The success of C-Topical as a local anesthetic solution suggests that it could become an important option for use by otolaryngologists (ear, nose and throat) physicians and specialists for office-based and in-patient procedures."
C-Topical is administered by means of cotton applicators, called pledgets.
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.
|